Fairvalue-Calculator Fairvalue-Calculator
EN DE

Compass Therapeutics, Inc (CMPX) Fair Value & Analysis

Healthcare · US · Market cap $364M

Price$2.02
Fair Value$1.04
Upside-48.5%
Quality95/100
Evidence: Low Range $0.6900 – $1.30

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Compass Therapeutics, Inc (CMPX) currently trades at $2.02, while our model-based Fair Value estimate is $1.04 — implying the stock looks roughly 48.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Compass Therapeutics, Inc (CMPX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.04 versus a price of $2.02 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CMPX?
Our 21-model fair value for Compass Therapeutics, Inc is $1.04 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.02.
What is the quality score of CMPX?
Compass Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.